Cost-Effectiveness of HIV Testing and Treatment in the United States
Open Access
- 15 December 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (Supplement), S248-S254
- https://doi.org/10.1086/522546
Abstract
In September 2006, the US Centers for Disease Control and Prevention (CDC) released new guidelines calling for routine, voluntary human immunodeficienThis publication has 36 references indexed in Scilit:
- The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United StatesMedical Care, 2006
- The Survival Benefits of AIDS Treatment in the United StatesThe Journal of Infectious Diseases, 2006
- Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and ReferralMedical Decision Making, 2005
- Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral TherapyThe New England Journal of Medicine, 2005
- Expanded Screening for HIV in the United States — An Analysis of Cost-EffectivenessThe New England Journal of Medicine, 2005
- The Case for Earlier Treatment of HIV InfectionClinical Infectious Diseases, 2004
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseThe New England Journal of Medicine, 2001
- Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency VirusClinical Infectious Diseases, 2001
- The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS PatientsMedical Decision Making, 1997
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996